BioSpace News Archive

Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic-derived therapies for use in the treatment of mental health, is pleased to announce the FDA’s authorization of the IND application submitted by collaborator Dr. Peter Hendricks.

Elegen, a leader in DNA innovation, today announced that it has successfully concluded its early access program and is now offering global commercial access to its new class of double-stranded DNA, developed to power the synthetic biology revolution.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening.

Diabeloop, a pioneer in Automated Insulin Delivery, will collaborate with leading global healthcare company, Novo Nordisk.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time,

Quoin Pharmaceuticals Ltd. today announces the dosing of the first patient in its open label clinical trial in Netherton Syndrome patients.

Qualigen Therapeutics, Inc. today announces the United States Patent and Trademarks Office (USPTO) has granted the Company patent number 11,560,380 for QN-302, its lead oncology investigational drug candidate, a small molecule selective transcription inhibitor with strong binding affinity to G4 complexes prevalent in cancer cells being investigated for solid tumors, including pancreatic cancer.

Enable Biosciences, a biotechnology company dedicated to developing innovative diagnostics, announced the relaunch of its website, type1testing.enablebiosciences.com , which offers an at-home testing kit for the early detection of type 1 diabetes.

Nuritas’ second clinical offers the most effective solution ever discovered for muscle health

Moleculin Biotech, Inc. today announced that an abstract regarding the Company’s next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.